← All trials
NCT04438850
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Aug 31, 2020
- Completion date
- Oct 31, 2020
- First posted
- Jun 19, 2020
- Last posted
- Jun 19, 2020
- Enrollment
- 102
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sacro Cuore Don Calabria General HospitalLead sponsor
- Mario Negri InstituteCollaborator
- Sacro Cuore Don Calabria General HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.